- Home
- ULCC vs PRAX Comparison
ULCC vs PRAX Comparison
Compare ULCC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- PRAX
- Stock Information
- Founded
- ULCC 1994
- PRAX 2015
- Country
- ULCC United States
- PRAX United States
- Employees
- ULCC N/A
- PRAX N/A
- Industry
- ULCC Air Freight/Delivery Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- ULCC Consumer Discretionary
- PRAX Health Care
- Exchange
- ULCC Nasdaq
- PRAX Nasdaq
- Market Cap
- ULCC 719.5M
- PRAX 599.7M
- IPO Year
- ULCC 2021
- PRAX 2020
- Fundamental
- Price
- ULCC $3.88
- PRAX $38.35
- Analyst Decision
- ULCC Hold
- PRAX Strong Buy
- Analyst Count
- ULCC 11
- PRAX 10
- Target Price
- ULCC $5.67
- PRAX $116.50
- AVG Volume (30 Days)
- ULCC 4.8M
- PRAX 421.5K
- Earning Date
- ULCC 05-01-2025
- PRAX 05-02-2025
- Dividend Yield
- ULCC N/A
- PRAX N/A
- EPS Growth
- ULCC N/A
- PRAX N/A
- EPS
- ULCC 0.30
- PRAX N/A
- Revenue
- ULCC $3,822,000,000.00
- PRAX $8,122,000.00
- Revenue This Year
- ULCC $9.75
- PRAX N/A
- Revenue Next Year
- ULCC $12.72
- PRAX $789.73
- P/E Ratio
- ULCC $13.01
- PRAX N/A
- Revenue Growth
- ULCC 5.99
- PRAX 270.02
- 52 Week Low
- ULCC $2.79
- PRAX $26.70
- 52 Week High
- ULCC $10.26
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- ULCC 53.27
- PRAX 53.31
- Support Level
- ULCC $2.97
- PRAX $34.89
- Resistance Level
- ULCC $3.68
- PRAX $40.89
- Average True Range (ATR)
- ULCC 0.25
- PRAX 2.30
- MACD
- ULCC 0.18
- PRAX 0.70
- Stochastic Oscillator
- ULCC 96.58
- PRAX 57.95
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.